TLSI - NASDAQ
TriSalus Life Sciences, Inc.
$3.18
-0.47%TriSalus Life Sciences, Inc., an immunotherapy company that develops and commercializes immunotherapies for the treatment of liver and pancreatic tumors. The company offers the TriNav Infusion System for hepatic arterial infusion of liver tumors; and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. It also develops SD-101, an investigational immunotherapeutic with pressure-enabled drug delivery technology for hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company is based in Westminster, Colorado.
At a Glance
Live SnapshotTriSalus Life Sciences, Inc. Management Team
Dr. Richard B. Marshak M.B.A., MBA, VMD
Chief Commercial Officer
Ms. Mary T. Szela B.S.N., M.B.A.
Chief Executive Officer, President & Director
Compensation
$624,044
Mr. James E. Young
Chief Financial Officer, Secretary & Treasurer
Ms. Jennifer L. Stevens J.D.
Chief Regulatory Officer
Compensation
$629,995
Ms. Jodi Devlin
Chief of Clinical Strategy & Operations
Compensation
$651,719
Dr. Bryan F. Cox Ph.D.
Chief of Research
Ms. Lori Ann Santamaria
Vice President of Operations
TriSalus Life Sciences, Inc. Insider Positioning
During the last 12 months, insiders have purchased $4.33M and sold $136K worth of TLSI shares, resulting in $4.20M of net buying activity.
3 Months
470.0K
1.18M
34.2K
135.80K
+1.0M
+$1.04M
3-6 Months
318.3K
1.30M
0
0.00
+1.3M
+$1.30M
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
353.9K
1.85M
0
0.00
+1.8M
+$1.85M
Top Buyers
Stansky Michael P
Director
$2.02M
Patience David
Officer: Chief Financial Officer
$1.29M
Wahlstrom Mats
Director
$234K
Valle William
Director
$207K
Szela Mary T
Director, Officer: Ceo And President
$125K
Top Sellers
Szela Mary T
Director, Officer: Ceo And President
$79K
Marshak Richard
Officer: Chief Commercial Officer
$16K
Stevens Jennifer
Officer: Chief Regulatory Officer
$15K
Devlin Jodi
Officer: Chief Of Clinical Operations
$13K
Cox Bryan F.
Officer: Chief Of Research
$13K
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $4.20M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Exceptional buy/sell ratio. Buying dramatically outweighs selling—one of the strongest possible insider signals.
Recent Trend (3 Months)
Very strong recent buying momentum. Recent insider purchases significantly outpace sales, suggesting near-term optimism.
Insider Participation
5 insider buyers and 5 sellers. Equal participation suggests mixed or neutral insider views.
Insider Activity Insight
Strong confluence of bullish signals: High buy/sell ratio, multiple insiders participating, and recent buying momentum all point to significant insider confidence. This level of coordinated buying often precedes positive developments.
SEC Filings
TLSI - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2025 N/A | March 31, 2026 | December 31, 2025 | 2025 | |
DEF 14A DEF 14A 2025 N/A | April 30, 2025 | June 12, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | July 19, 2024 | July 10, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | May 24, 2023 | June 12, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | November 07, 2022 | December 07, 2022 | 2022 | |
DEF 14A DEF 14A 2022 N/A | February 14, 2022 | March 09, 2022 | 2022 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.